N

Minerva Neurosciences
D

NERV

2.39000
USD
0.06
(2.58%)
Market Closed
Volume
0
EPS
-0
Div Yield
-
P/E
-5
Market Cap
16,714,240
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    E
    ESPR
    0.03000
    (1.43%)
    2.13000 USD
    I
    IONS
    -2.970
    (-7.97%)
    34.290 USD
    S
    SAGE
    -0.26000
    (-4.84%)
    5.11000 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    More
News

Title: Minerva Neurosciences

Sector: Healthcare
Industry: Biotechnology
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.